Contact information

Email
freddie.hamdy@nds.ox.ac.uk

Telephone
+44 (0)1865 617123
Fax +44 (0)1865 617125

PA
Nicky Iyer
nicky.iyer@nds.ox.ac.uk

LOCATION

Old Road Campus Research Building (off Roosevelt Drive), Churchill Hospital, Headington, Oxford, OX3 7DQ

Research groups

Colleges

Balliol College

Biography

I joined Oxford in October 2008 as Head of the Nuffield Department of Surgery, Nuffield Professor of Surgery, Professor of Urology and Honorary Consultant Urological Surgeon at the Oxford Radcliffe Hospitals as well as Fellow of Balliol College. I spent the past 10 years as founding Chair of Urology and was Director of the Division of Clinical Sciences, then Head of Oncology at the University of Sheffield. I trained in Surgery and Urology at Liverpool, Sheffield and Newcastle.

I have authored over 200 peer-reviewed articles, and raised to date over £40m in peer-reviewed grants.

Memberships

British Association of Urological Surgeons
British Medical Association
European Association of Urology
American Urological Association
Association of Academic European Urologists
Deutsche Gesellschaft für Urologie (German Urological Society)

Freddie Hamdy CBE

MBChB, LRCP-LRCSEd, LRCPSGlasg, FRCSEd, FRCSEng, MD (Shef), MA (Oxon) FRCSEd (Urol), FMedSci

Head of Department

Nuffield Professor of Surgery
Professor of Urology

My research focuses on management of urological malignancies, in particular prostate and bladder cancer.

Each year about 10,000 people in the UK are diagnosed with bladder cancer and about 40,000 men are diagnosed with prostate cancer, with prostate cancer being the the most common cancer in men.

My laboratory interest is the mechanisms of invasion/metastasis in prostate cancer and the interaction between primary prostate cancer cells and the bone microenvironment, as well as epigenetics of bladder cancer.

My clinical research interest is to provide evidence of treatment effectiveness in prostate cancer through large randomized controlled trials.

I am the Chief Investigator of many studies including the ProtecT (Prostate testing for cancer and Treatment) study of case-finding and randomised controlled trial of treatment effectiveness in prostate cancer - the largest of its kind worldwide. I am also establishing various multidisciplinary research platforms at Oxford and introducing, with colleagues, a new centre for evaluation of minimally invasive technology including robotic surgery.

Awards

1995 - AUA/EAU Academic Exchange Fellowship
1996 - EAU Crystal Matula Award
2001 - Golden Telescope award, BAUS
2007 - Fellow of the Academy of Medical Sciences
2012 - St Peter’s Medal, BAUS
2017 - NIHR Senior Investigator Emeritus
2015 - Elected Member, American Association of GU surgeons
2018 - Marberger Prize, Association of Academic European Urologists (AAEU)
2018 - Willy Gregoir Medal, European Association of Urology
2022 - Medal for Excellence Award, British Association of Surgical Oncology (BASO)
2022 - Laurent Boccon-Gibod Medal, Association of Academic European Urologists (AAEU)
2024 - CBE (Commander of the Order of the British Empire) – for services to surgical and cancer sciences

View publications on PubMed

Key publications

First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy.

Hamdy FC. et al, (2024), Eur J Nucl Med Mol Imaging, 51, 3009 - 3025

Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.

Martin RM. et al, (2024), JAMA, 331, 1460 - 1470

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features.

Rao S. et al, (2024), Genome Med, 16

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Hamdy FC. et al, (2023), N Engl J Med, 388, 1547 - 1558

Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.

Donovan JL. et al, (2023), NEJM Evid, 2

Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.

Sooriakumaran P. et al, (2022), BJU Int, 130, 43 - 53

prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.

Donovan JL. et al, (2018), J Clin Epidemiol, 96, 35 - 46

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.

Martin RM. et al, (2018), JAMA, 319, 883 - 895

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Hamdy FC. et al, (2016), N Engl J Med, 375, 1415 - 1424

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Donovan JL. et al, (2016), N Engl J Med, 375, 1425 - 1437

Recent publications

Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial.

Bryant RJ. et al, (2025), Lancet Oncol, 26, 583 - 595

Integrating multiparametric MRI with spatial transcriptomics to identify “Radio-Spatial Genomic” features of prostate cancer using artificial intelligence

Anbarasan T. et al, (2025), Cancer Research, 85

Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of epithelial cancers.

Erickson A. et al, (2025), PLoS One, 20

Mapping clonal heterogeneity and stromal dynamics in prostate cancer

Figiel S. et al, (2025), CANCER RESEARCH, 85

Stress-Induced Rab11a-Exosomes Induce Amphiregulin-Mediated Cetuximab Resistance in Colorectal Cancer (vol 13, e12465, 2024)

Mason JD. et al, (2025), JOURNAL OF EXTRACELLULAR VESICLES, 14

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.

Srinivasan S. et al, (2024), Nat Commun, 15

Flourine-18 Prostate-Specific Membrane Antigen-1007 Positron Emission Tomography Imaging in Staging of Primary and Secondary Prostate Cancer-A Retrospective Observational Cohort Study.

Byrne MHV. et al, (2024), JU Open Plus, 2

Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities.

Cussenot O. et al, (2024), Eur Urol Oncol, 7, 978 - 981

'Case of the Month' from the Department of Urology, Oxford University Hospitals, Oxford, UK: stereotactic radiotherapy to the vas deferens for PSMA-PET CT detected local recurrence 10 years after radical prostatectomy.

Bates AS. et al, (2024), BJU Int, 134, 377 - 379

First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy.

Hamdy FC. et al, (2024), Eur J Nucl Med Mol Imaging, 51, 3009 - 3025

Delphi consensus project on prostate-specific membrane antigen (PSMA)-targeted surgery-outcomes from an international multidisciplinary panel.

Berrens A-C. et al, (2024), Eur J Nucl Med Mol Imaging, 51, 2893 - 2902

Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur Urol. 2024;85:565-573.

Cussenot O. et al, (2024), Eur Urol, 86, e48 - e49

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.

Charlton PV. et al, (2024), Prostate, 84, 977 - 990

Screening and active surveillance in prostate cancer: the dilemma continues.

Hamdy FC. et al, (2024), BJU Int, 134, 1 - 2

Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.

Mason JD. et al, (2024), J Extracell Vesicles, 13

Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.

Martin RM. et al, (2024), JAMA, 331, 1460 - 1470

PD09-08 SPATIAL TRANSCRIPTOMIC CLONAL DECONVOLUTION IDENTIFIES THE ‘LETHAL CLONE’ IN PROSTATE CANCER AS DEFINED BY ABILITY TO METASTASIZE TO LYMPH NODES

Yin W. et al, (2024), Journal of Urology, 211

PD09-06 EXPLORING STROMAL DYNAMICS IN PROSTATE CANCER: INSIGHTS FROM SPATIAL TRANSCRIPTOMIC ANALYSES

Figiel S. et al, (2024), Journal of Urology, 211

Genomic evolution shapes prostate cancer disease type.

Woodcock DJ. et al, (2024), Cell Genom, 4

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features.

Rao S. et al, (2024), Genome Med, 16

Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.

Hamdy FC. and Donovan JL., (2024), Eur Urol, 85, e41 - e42

Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.

Hamdy FC. and Donovan JL., (2024), Eur Urol, 85, e54 - e55

Stress-induced extracellular vesicles promote EGFR-ERK dependent growth and cetuximab resistance in colorectal cancer

Mason J. et al, (2024), BRITISH JOURNAL OF SURGERY, 111

Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?

Cussenot O. et al, (2023), BJU Int, 132, 472 - 484

Endemic statistical paradoxes in epidemiologic studies distort knowledge on prostate cancer: mitigation and caution of fallacies in prostate cancer causal epidemiological studies.

Cussenot O. et al, (2023), Curr Opin Urol, 33, 421 - 427

Decision Making in Prostate Cancer.

Nadamuni M. et al, (2023), N Engl J Med, 389, 1335 - 1338

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures.

Figiel S. et al, (2023), Mol Cancer, 22

Beyond attention: deriving biologically interpretable insights from weakly-supervised multiple-instance learning models

Bonnaffé W. et al, (2023)

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease

Charlton P. et al, (2023)

Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.

Rao SR. et al, (2023), Int J Mol Sci, 24

Geometric anatomy basis for safe and effective focal ablation of prostate cancer by irreversible electroporation (IRE)

Cussenot O. et al, (2023), Anatomia, 2, 232 - 242

Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply.

Hamdy FC. and Donovan JL., (2023), N Engl J Med, 389

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Thorn JC. et al, (2023), BMC Health Serv Res, 23

Rbf/E2F1 control growth and endoreplication via steroid-independent Ecdysone Receptor signalling in Drosophila prostate-like secondary cells.

Sekar A. et al, (2023), PLoS Genet, 19

Correction: The landscape of viral associations in human cancers.

Zapatka M. et al, (2023), Nat Genet, 55

Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk.

Cussenot O. et al, (2023), BJU Int, 131, 745 - 754

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of heterogeneity on genomic signature scoring

Figiel S. et al, (2023)

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole genome sequencing with histopathological features

Rao S. et al, (2023)

Author Correction: Pan-cancer analysis of whole genomes.

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium ., (2023), Nature, 614

Intermediate-risk Prostate Cancer-A Sheep in Wolf's Clothing?

Heidegger I. et al, (2023), Eur Urol Oncol, 6, 103 - 109

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of heterogeneity on genomic signature scoring

Figiel S. et al, (2023), European Urology, 83, S1793 - S1794

The Detection of Prostate Cancer With Magnetic Resonance Imaging-targeted Prostate Biopsies Is Superior With the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study

Bryant RJ. et al, (2023), JOURNAL OF UROLOGY, 209

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.

Keeney E. et al, (2022), Pharmacoeconomics, 40, 1207 - 1220

The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.

Buhigas C. et al, (2022), Mol Cancer, 21

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).

Lane JA. et al, (2022), BJU Int, 130, 370 - 380

Spatially resolved clonal copy number alterations in benign and malignant tissue.

Erickson A. et al, (2022), Nature, 608, 360 - 367

Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.

Burns D. et al, (2022), Eur Urol, 82, 201 - 211

Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.

Sooriakumaran P. et al, (2022), BJU Int, 130, 43 - 53

Automated quality assessment of large digitised histology cohorts by artificial intelligence.

Haghighat M. et al, (2022), Sci Rep, 12

Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.

Whitburn J. et al, (2022), Sci Adv, 8

Precision surgery: the role of intra-operative real-time image guidance - outcomes from a multidisciplinary European consensus conference.

Dell'Oglio P. et al, (2022), Am J Nucl Med Mol Imaging, 12, 74 - 80

Prostate-Specific Antigen Testing for Prostate Cancer Screening-Is the Message Getting Through?

Hamdy FC., (2022), JAMA Oncol, 8, 47 - 49

The spatial landscape of clonal somatic mutations in benign and malignant tissue

Erickson A. et al, (2022), CANCER RESEARCH, 82

More publications

Cookies on this website